Loading...
•
Mar 31, 2024
Atricure Q1 2024 Earnings Report
AtriCure reported a strong start to 2024 with revenue growth across all franchises worldwide.
Key Takeaways
AtriCure reported a strong start to 2024, with worldwide revenue increasing by 16.4% year-over-year. U.S. revenue grew by 15.4%, driven by key product lines. International revenue increased by 21.5%.
Worldwide revenue increased by 16.4% year-over-year to $108.9 million.
U.S. revenue increased by 15.4%, driven by sales across key product lines.
International revenue increased by 21.5% with robust activity across all franchises and geographic regions.
Adjusted EBITDA increased by $0.9 million over the first quarter of 2023, reaching $2.8 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Full year 2024 revenue is projected to be approximately $459 million to $466 million, reflecting growth of approximately 15% to 17% over full year 2023. Full year 2024 Adjusted EBITDA is expected to be approximately $26 million to $29 million, with improvements annually thereafter. Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.82.
Positive Outlook
- Revenue is projected to grow by approximately 15% to 17% over full year 2023.
- Adjusted EBITDA is expected to improve annually.
- Adjusted EBITDA represents an approximately 34% to 49% increase over full year 2023.
Challenges Ahead
- Adjusted loss per share is expected to be in the range of $0.74 to $0.82.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...